Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | HPGD | P15428 | 3/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576116 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6934910 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL251703 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL4575415 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6557493 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6369045 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL4576333 | 1.00 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| Hydrochloric Acid SCHEMBL4576952 | 0.99 | CYP1A2 (0.74) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL4575922 | 0.92 | OPRM1 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 | |
| SCHEMBL6935975 | 0.92 | OPRM1 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | ENTA HOLDING LLC | 2008-08-14 | — | — | US | claimed |
| US-6919350-B2 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-0938317-B1 | COMPOSITIONS FOR REDUCING RESPIRATORY DEPRESSION | ARDENT PHARMACEUTICALS INC (US) | 2004-03-03 | — | — | EP | claimed |
| US-20020111359-A1 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | US | claimed |
| US-6300332-B1 | DRUG MEDIATED RESPIRATORY DEPRESSION, MUSCLE RIGIDITY AND NAUSEA/VOMITING AND SIDE EFFECT REDUCTION | DELTA PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | claimed |
| EP-1003373-A4 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS INC (US) | 2000-09-20 | — | — | EP | claimed |
| EP-0938317-A4 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS INC (US) | 2000-08-23 | — | — | EP | claimed |
| EP-1003373-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0938317-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1999-09-01 | — | — | EP | claimed |
| WO-1999001033-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| US-5807858-A | DIARYLMETHYLPIPERAZINE AND PIPERIDINE COMPOUNDS; SIDE EFFECTREDUCTION OF ANALGESICS | DELTA PHARMACEUTICAL, INC. (US) | 1998-09-15 | — | — | US | claimed |
| WO-1997046240-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | claimed |
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296707-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-8865721-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC (US) | 2014-01-30 | — | — | US | disclosed |
| EP-0938317-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1999001033-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| US-5807858-A | DIARYLMETHYLPIPERAZINE AND PIPERIDINE COMPOUNDS; SIDE EFFECTREDUCTION OF ANALGESICS | DELTA PHARMACEUTICAL, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1997046240-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111359-A1 | Side effect reduction of narcotics | OPRD1, OPRM1, OPRK1 | CYP1A2 758/4885CYP3A4 814/4885CYP2C9 1635/4885 |
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP1A2 760/4885CYP3A4 675/4885CYP2C9 1013/4885 |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP1A2 751/4885CYP3A4 866/4885CYP2C9 1380/4885 |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | CYP1A2 760/4885CYP3A4 675/4885CYP2C9 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.